BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP

巴尔的摩儿童艾滋病临床试验组（BPACTG） 成立于1988年，是一个合作的努力，调查人员在 约翰霍普金斯大学和巴尔的摩的马里兰州大学。作为 艾滋病毒感染儿童的两个主要照料场所 在巴尔的摩大都市区和马里兰州，BPACTG已被 该地区几乎所有初级和专业护理的中心， 为婴儿提供了最先进的艾滋病毒特异性治疗， 儿童、青少年和孕妇。 BPACTG中的两个站点在其临床服务中具有相同的目标 和研究：提供最高质量的全面护理， 受艾滋病毒影响的家庭;对艾滋病毒感染的机制进行研究， 垂直获得性艾滋病毒感染的传播和发病机制;以及 开发和测试预防艾滋病毒的新疗法 疾病和艾滋病毒感染的传播。 BPACTG研究者积极参与ACTG的工作， 包括委员会和工作组。概念表和方案 开发和协议管理。BPACTG有50多名患者 积极参与ACTU方案，已入组117例 在最初的四年半的活动中。本文所述的研究 计划在四年内每年招募35-40名新患者， 拟议供资周期。拟议的研究将主要涉及 服务不足的患者群体：非裔美国人和女性。 咨询小组的优先领域是本建议的关键要素。的 BPACTG将继续参与围产期试验， 阻断艾滋病毒垂直传播，并建议增加 对围产期传播决定因素的发展研究。 开发新的抗逆转录病毒药物将是优先事项， BPACTG在未来四年内，将I/II期试验与拟议的 儿科药理学核心实验室。 对感染艾滋病毒的青少年的外联 将继续努力查明受感染的青少年， 将他们纳入BPACTG护理网络。 完善现有 神经发育评估工具和新测试的开发 仪器被纳入临床核心， 发展研究的组成部分。建立免疫学核心 疾病免疫标记物实验室和发展研究 提出了进展。 过去五年建立了一个有效的研究人员网络 和BPACTG中为艾滋病毒感染青年和孕妇提供服务的提供者 这个地区的母亲。这个组织有能力、有组织， 与社区建立必要的联系，以进行富有成效的研究， 将有助于提供更新，更有效的治疗方法来预防艾滋病毒 艾滋病的传播和减轻艾滋病毒疾病的负担， 人口

The Baltimore Pediatric AIDS Clinical Trials Group (BPACTG) was established in 1988 as a collaborative effort between investigators at The Johns Hopkins University and the University of Maryland at Baltimore. As the two predominant sites for care of HIV-infected children in the Baltimore metropolitan area and the state of Maryland, the BPACTG has been the center of nearly all primary and specialized care for the region and has provided access to the most advanced HIV-specific therapy for infants, children, teenagers, and pregnant mothers. Both sites in the BPACTG share the same goals in their clinical service and research: to provide comprehensive care of the highest quality to families affected by HIV; to conduct research into the mechanisms of transmission and pathogenesis of vertically-acquired HIV infection; and to develop and test new therapeutic modalities for the prevention of HIV disease and transmission of HIV infection. The BPACTG investigators participate actively in the ACTG effort, including committees and working groups. concept sheet and protocol development, and protocol administration. The BPACTG has over 50 patients actively participating in ACTU protocols, and 117 have been enrolled during the first 4 1/2 years of activity. The research described herein plans to enroll 35-40 new patients per year during the four years of proposed funding cycle. The proposed research will involve predominantly underserved patients groups: African-Americans and women. Areas of priority for the ACTG are key elements in this proposal. The BPACTG will continue to participate in perinatal trials attempting to interrupt vertical transmission of HIV, and propose additional developmental research into the determinants of perinatal transmission. Development of novel antiretroviral agents will be a priority for the BPACTG in the next four years, linking Phase I/II trials with the proposed pediatric pharmacology core laboratory. Outreach to adolescents with HIV will continue, with efforts directed at identifying infected teenagers and bringing them into the BPACTG care network. Refinement of existing neurodevelopmental assessment tools and development of new testing instruments is incorporated into the clinical core as well as developmental research components. Establishment of an immunology core laboratory and developmental research into immunologic markers of disease progression are proposed. The past five years have established an effective network of researchers and providers in the BPACTG who serve the HIV-infected youth and expectant mothers of this region. This group has the capabilities, organization, and linkages with the community necessary to conduct productive research which will help provide newer, more effective therapies to prevent HIV transmission and to ameliorate the burden of HIV disease in this population.